Spots Global Cancer Trial Database for Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease
Official Title:
Study ID: NCT00004409
Conditions
Interventions
Study Description
Brief Summary: OBJECTIVES: Evaluate the safety and efficacy of collagenase in improving flexion deformity, range of motion, and grip strength in patients with residual Dupuytren's disease.
Detailed Description: PROTOCOL OUTLINE: This is a randomized, investigator-blinded, placebo-controlled study. Patients receive a single dose of either collagenase or placebo into the target finger on day 0. Patients who do not respond at the 1 month follow up visit may receive an injection of open label collagenase, if IgE antibody levels are no greater than 15 ng/mL. Following treatment, patients use a nighttime extension splint for 4 months and perform finger flexion/extension exercises. Patients are followed at 1, 7, and 14 days, and at 1, 2, 3, 6, 9, and 12 months, for each joint treated. Completion date provided represents the completion date of the grant per OOPD records
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University Hospital, Palo Alto, California, United States
State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
Contact Details
Name: Lawrence C. Hurst
Affiliation: State University of New York
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
